192 related articles for article (PubMed ID: 32632918)
1. Cannabinoids in multiple sclerosis: A neurophysiological analysis.
Vecchio D; Varrasi C; Virgilio E; Spagarino A; Naldi P; Cantello R
Acta Neurol Scand; 2020 Oct; 142(4):333-338. PubMed ID: 32632918
[TBL] [Abstract][Full Text] [Related]
2. Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship.
Contin M; Mancinelli L; Perrone A; Sabattini L; Mohamed S; Scandellari C; Foschi M; Vacchiano V; Lugaresi A; Riva R
Clin Neuropharmacol; 2018; 41(5):171-176. PubMed ID: 30024443
[TBL] [Abstract][Full Text] [Related]
3. The effect of cannabinoids on the stretch reflex in multiple sclerosis spasticity.
Marinelli L; Mori L; Canneva S; Colombano F; Currà A; Fattapposta F; Bandini F; Capello E; Abbruzzese G; Trompetto C
Int Clin Psychopharmacol; 2016 Jul; 31(4):232-9. PubMed ID: 27003093
[TBL] [Abstract][Full Text] [Related]
4. Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.
Meuth SG; Henze T; Essner U; Trompke C; Vila Silván C
Int J Neurosci; 2020 Dec; 130(12):1199-1205. PubMed ID: 32065006
[No Abstract] [Full Text] [Related]
5. Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD).
Meyer T; Funke A; Münch C; Kettemann D; Maier A; Walter B; Thomas A; Spittel S
BMC Neurol; 2019 Sep; 19(1):222. PubMed ID: 31493784
[TBL] [Abstract][Full Text] [Related]
6. Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study.
Mallada Frechín J
Neurodegener Dis Manag; 2018 Jun; 8(3):151-159. PubMed ID: 29851356
[TBL] [Abstract][Full Text] [Related]
7. Clinical experiences with cannabinoids in spasticity management in multiple sclerosis.
Lorente Fernández L; Monte Boquet E; Pérez-Miralles F; Gil Gómez I; Escutia Roig M; Boscá Blasco I; Poveda Andrés JL; Casanova-Estruch B
Neurologia; 2014 Jun; 29(5):257-60. PubMed ID: 24035293
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.
Paolicelli D; Direnzo V; Manni A; D'Onghia M; Tortorella C; Zoccolella S; Di Lecce V; Iaffaldano A; Trojano M
J Clin Pharmacol; 2016 Jul; 56(7):845-51. PubMed ID: 26608223
[TBL] [Abstract][Full Text] [Related]
9. A randomised controlled cross-over double-blind pilot study protocol on THC:CBD oromucosal spray efficacy as an add-on therapy for post-stroke spasticity.
Marinelli L; Balestrino M; Mori L; Puce L; Rosa GM; Giorello L; Currà A; Fattapposta F; Serrati C; Gandolfo C; Abbruzzese G; Trompetto C
BMJ Open; 2017 Sep; 7(9):e016843. PubMed ID: 28882919
[TBL] [Abstract][Full Text] [Related]
10. Long-term assessment of the cognitive effects of nabiximols in patients with multiple sclerosis: A pilot study.
Alessandria G; Meli R; Infante MT; Vestito L; Capello E; Bandini F
Clin Neurol Neurosurg; 2020 Sep; 196():105990. PubMed ID: 32526487
[TBL] [Abstract][Full Text] [Related]
11. Sativex
Markovà J; Essner U; Akmaz B; Marinelli M; Trompke C; Lentschat A; Vila C
Int J Neurosci; 2019 Feb; 129(2):119-128. PubMed ID: 29792372
[TBL] [Abstract][Full Text] [Related]
12. Sativex(®) and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis.
Leocani L; Nuara A; Houdayer E; Schiavetti I; Del Carro U; Amadio S; Straffi L; Rossi P; Martinelli V; Vila C; Sormani MP; Comi G
J Neurol; 2015 Nov; 262(11):2520-7. PubMed ID: 26289497
[TBL] [Abstract][Full Text] [Related]
13. Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study.
Patti F; Chisari CG; Solaro C; Benedetti MD; Berra E; Bianco A; Bruno Bossio R; Buttari F; Castelli L; Cavalla P; Cerqua R; Costantino G; Gasperini C; Guareschi A; Ippolito D; Lanzillo R; Maniscalco GT; Matta M; Paolicelli D; Petrucci L; Pontecorvo S; Righini I; Russo M; Saccà F; Salamone G; Signoriello E; Spinicci G; Spitaleri D; Tavazzi E; Trotta M; Zaffaroni M; Zappia M;
Neurol Sci; 2020 Oct; 41(10):2905-2913. PubMed ID: 32335779
[TBL] [Abstract][Full Text] [Related]
14. THC/CBD oromucosal spray in patients with multiple sclerosis overactive bladder: a pilot prospective study.
Maniscalco GT; Aponte R; Bruzzese D; Guarcello G; Manzo V; Napolitano M; Moreggia O; Chiariello F; Florio C
Neurol Sci; 2018 Jan; 39(1):97-102. PubMed ID: 29052091
[TBL] [Abstract][Full Text] [Related]
15. Application device for THC:CBD oromucosal spray in the management of resistant spasticity: pre-production testing.
Montero-Escribano P; Vila Silván C
Expert Rev Med Devices; 2019 Sep; 16(9):835-840. PubMed ID: 31393179
[No Abstract] [Full Text] [Related]
16. A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis.
Gras A; Broughton J
Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):771-779. PubMed ID: 26750641
[TBL] [Abstract][Full Text] [Related]
17. Placebo effects in a multiple sclerosis spasticity enriched clinical trial with the oromucosal cannabinoid spray (THC/CBD): dimension and possible causes.
Di Marzo V; Centonze D
CNS Neurosci Ther; 2015 Mar; 21(3):215-21. PubMed ID: 25475413
[TBL] [Abstract][Full Text] [Related]
18. Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study.
Lus G; Cantello R; Danni MC; Rini A; Sarchielli P; Tassinari T; Signoriello E
Neurodegener Dis Manag; 2018 Apr; 8(2):105-113. PubMed ID: 29683408
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis.
Conte A; Bettolo CM; Onesti E; Frasca V; Iacovelli E; Gilio F; Giacomelli E; Gabriele M; Aragona M; Tomassini V; Pantano P; Pozzilli C; Inghilleri M
Eur J Pain; 2009 May; 13(5):472-7. PubMed ID: 18603457
[TBL] [Abstract][Full Text] [Related]
20. A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis.
Arroyo González R
Expert Rev Neurother; 2018 Oct; 18(10):785-791. PubMed ID: 30235965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
